Gene-edited stem cells program the immune system to fight disease

Summary

Our immune system relies on B cells to act as tiny factories, churning out antibodies to fight off infections. But for some viruses, like HIV, our bodies struggle to make the right antibodies naturally. Scientists have developed a potential workaround. By taking blood-forming stem cells, known as hematopoietic stem and progenitor cells, and editing their genes, researchers were able to program these cells to produce highly effective therapeutic antibodies.

In a recent study using mice, researchers engineered these stem cells to carry the instructions for a powerful antibody that neutralizes HIV. When they transplanted just a few hundred of these edited cells into the mice, the cells settled in and became B cell precursors. After the mice were exposed to an HIV protein, these customized immune cells multiplied and produced high levels of the protective antibody. When the antibody levels eventually started to drop, a simple booster shot kept the production going strong for at least nine months.

The technique proved highly adaptable. Researchers found they could mix different batches of engineered cells to produce multiple antibodies at once, creating a multilayered defense against HIV. They also successfully programmed cells to fight off malaria and influenza, with the flu antibodies protecting the mice from what would have been a lethal infection. Importantly, this is an early-stage proof of concept. The experiments have only been conducted in mice, requiring much more research before we know if it will work in humans.

Why it matters.

If this approach can be safely translated to humans, it could revolutionize how we prevent and treat diseases that have historically evaded traditional vaccines. Currently, administering therapeutic antibodies requires regular infusions because the proteins eventually clear from the body. This new method could act as a living drug. A single stem cell transplant could embed directly into the patient, creating a permanent, on-demand supply of protective antibodies that can be awakened with a standard booster shot.

The versatility of this platform is especially promising for global health. The ability to mix different engineered stem cells means researchers could potentially create custom immune defenses against complex viruses that mutate easily. While clinical trials are still a long way off, this research opens a fascinating new door for cellular therapies, offering a glimpse into a future where we can upgrade our own immune system to fight off some of the world's most stubborn infectious diseases.

From the source

The story in numbers.

Minimum HSPCs transplanted to establish expressing B cells: a few hundred
Duration of maintained antibody production post-boost: 9 months
Pathogen targets tested (HIV, malaria, influenza): 3

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

First inside-the-body CRISPR gene therapy heads to the FDA

Intellia Therapeutics is making medical history as it seeks approval from the US Food and Drug Administration for a groundbreaking genetic treatment. The drug, called lonvoguran ziclumeran or lonvo-z, is the first CRISPR-based gene therapy designed to work "in vivo," meaning the genetic editing happens directly inside the human body. CRISPR is a biological tool that allows scientists to make precise changes to DNA. Intellia is using this technology to treat hereditary angioedema, a genetic condition that causes severe and unpredictable swelling attacks. The company recently completed a Phase 3 clinical trial, which is the final testing step before seeking regulatory approval. In the study, a single dose of lonvo-z reduced swelling attacks by 87 percent compared to a placebo over a six-month period. Even more strikingly, 62 percent of the patients who received the treatment had absolutely no attacks during those six months and were able to completely stop taking their usual preventative medications. While these numbers are highly encouraging, the research does come with a few early caveats. The trial was relatively small, involving a total of 80 patients, with 52 receiving the actual therapy and 28 given a placebo. Additionally, the currently reported results only track the patients for six months. Researchers will need to monitor these individuals for a longer period to confirm that the single dose continues to work safely and effectively over time.

Nature Biotechnology2 min read

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News1 min read

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN1 min read

Follow your curiosity.

Gene-edited stem cells program the immune system to fight disease

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

A little science goes a long way.